Loading company…
PAM Theragnostics researches diagnostic and therapeutic approaches involving the PAM enzyme.
Founded in 2020 and based in Berlin, Germany, PAM Theragnostics researches diagnostic and therapeutic approaches related to amidated peptide hormones and the PAM enzyme. Its work focuses on developing tools for early diagnosis and treatment of Alzheimer's Disease. In January 2022, it raised EUR 1.5 million in Series A funding led by Brandenburg Kapital.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in